Fourth quarter and full year report 2025

Vitrolife reported Q4 sales of SEK 891m (959) and full-year sales of SEK 3,440m (3,609) with organic growth of ~6% in Q4 and 4% FY excluding discontinued business, while reported sales were depressed by significant FX effects (-10% Q4, -6% FY). EBITDA declined to SEK 196m in Q4 (EBITDA margin 22.0%) and SEK 949m FY (27.6%), and the company booked a SEK 5,357m impairment that drove a Q4 net loss of SEK -5,314m (EPS -39.24) and FY net loss of SEK -5,013m (EPS -37.01); underlying net income excluding the impairment and restructuring was positive. The Board proposes an unchanged dividend of SEK 1.10 per share; however, the large non-cash impairment and associated restructuring will likely be the primary driver of near-term equity volatility.

Analysis

Market structure: Vitrolife’s print reallocates winners toward large, diversified medtech and consumables-heavy players—companies with >50% recurring consumables revenue (e.g., CooperCompanies (COO), Thermo Fisher) gain share as customers favor stable suppliers. Vitrolife’s Q4 FX hit (-10% quarter; -6% FY) and a 320–640 bps EBITDA margin compression signal limited near-term pricing power in EMEA and currency pass-through inability; consumables growth (+10% Q4) suggests demand is intact but profitability is FX-limited. Distributors and small EMEA clinics that lost access (discontinued markets) are near-term losers; regional mix shift (Americas +9%, APAC +10% Q4) favors USD/flow-exposed producers.

Risk assessment: Tail risks include further goodwill/asset impairments (>SEK 5.4bn already) or covenant/default scenarios if cash flow weakens—monitor net debt/interest coverage over next 30–90 days; regulatory recalls in reproductive devices (low probability, high impact) could force additional write-offs. Immediate (days) volatility will be driven by sentiment and FX; short-term (weeks–months) depends on AGM/dividend outcome and Q1'26 sales vs. FX; long-term hinges on successful SEK-driven restructuring and normalization of FX rates. Hidden dependencies: distributor contract rollovers in EMEA and localized reimbursement changes may amplify revenue downside.

Trade implications: Primary tactical trade is to short VITR (Nasdaq Stockholm: VITR) or buy puts—establish a 3–5% portfolio short-sized exposure via 3–6 month put spreads if the stock fails to recover 20% within 10 trading days, targeting 25–40% downside. Pair trade: long COO (2–4% position) or MRK.DE (2–4%) vs short VITR to capture operational resilience and FX insulation. Options: sell covered calls on long MRK.DE/IHI exposure to fund protective VITR puts; prefer 3–6 month expiries to capture near-term catalysts (AGM, Q1). Rotate out of small-cap Nordic medtechs into IHI or MRK.DE to reduce idiosyncratic impairment risk.

Contrarian angle: Market may be over-penalizing operational cash flow—adjusted FY net income ex-impairment was SEK 390m and operating cash flow still SEK 635m, suggesting insolvency risk is low; if VITR equity is down >40% from pre-release levels, consider opportunistic 1–2% long via 12–18 month LEAP calls or buy-write to capture recovery once impairment is digested. Historical precedent: medtechs often recover within 6–12 months after large one-time impairments if core consumables demand persists. Watch for unintended consequence: maintaining dividend (SEK 149m) could limit restructuring flexibility—if management keeps payout despite cash stress, downside increases.

Key Decisions for Investors

• Establish a 3–5% portfolio short position in VITR (Nasdaq Stockholm: VITR) via stock or 3–6 month put spreads (buy 1x ATM put, sell 1x OTM put) if price does not regain +20% within 10 trading days; target profit 25–40% or cover if EBITDA margin recovery >200 bps QoQ.
• Deploy 2–4% long positions in CooperCompanies (COO) or Merck KGaA (MRK.DE) within 5 trading days to capture defensive consumables exposure; fund with proceeds from VITR short and sell 3-month covered calls to reduce cost-basis.
• If VITR equity is down >40% from pre-release, open a 1–2% opportunistic long via 12–18 month LEAP calls or buy-write (purchase stock and sell 9–12 month calls) because adjusted operating cash flow (SEK 635m) suggests downside may be overdispriced; exit/trim if management funds dividend from cash below 2x quarterly operating cash flow.
• Reduce small-cap Nordic medical-device exposure by 30–50% and rotate into IHI (iShares US Medical Devices ETF) over 2–4 weeks to lower idiosyncratic impairment risk; re-evaluate after Q1’26 results and FX movement (watch SEK vs USD/EUR; act if SEK strengthens >3% which would benefit VITR).